WeVote
Log In

Bill

JB

Bill

S 1192

Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.

2024-2025 Regular Session Introduced by Jon Bramnick and 8 co-sponsors

Bill eliminates prior authorization and step therapy requirements for serious mental illness medications, removing insurance barriers to prescription access but potentially raising drug costs.

Senate Amendment (Voice) (Ruiz)
#mentalhealt #pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · S 1192

Legislative bill overview

S 1192 mandates that health insurance plans in New Jersey cover prescription medications for serious mental illnesses without requiring prior authorization or utilization management techniques like step therapy (where insurers require patients to try cheaper drugs first). The bill aims to streamline access to mental health medications by removing administrative barriers that can delay treatment.

Why is this important

Mental illness affects millions of New Jersey residents, and delayed medication access can worsen outcomes and increase emergency care use. Prior authorization and step therapy requirements, while designed to control costs, can create treatment gaps during critical periods. This bill directly impacts both patients seeking timely mental health care and insurers managing prescription drug costs.

Potential points of contention

  • Cost implications: Removing utilization management tools may increase insurance premiums or drug costs, with unclear fiscal impact on insurers and ultimately on consumers and employers
  • Definition of "serious mental illness": The bill's scope depends on how this term is defined—overly broad definitions could significantly expand coverage requirements, while narrow ones may exclude conditions patients and advocates consider serious
  • Trade-offs with other cost controls: Eliminating step therapy removes one mechanism insurers use to encourage generic/lower-cost alternatives, potentially reducing incentives for cost-effective prescribing and increasing overall drug spending

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.